Acquired ATTR amyloidosis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 18 Jun 2026 04:07:40 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Acquired ATTR amyloidosis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A Study of Acoramidis for Long-Term Safety in Patients with Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy https://clinicaltrials.eu/trial/a-study-of-acoramidis-for-long-term-safety-in-patients-with-newly-diagnosed-variant-transthyretin-amyloid-cardiomyopathy/ Wed, 29 Apr 2026 15:07:41 +0000 https://clinicaltrials.eu/trial/a-study-of-acoramidis-for-long-term-safety-in-patients-with-newly-diagnosed-variant-transthyretin-amyloid-cardiomyopathy/ This study involves people with Transthyretin Amyloidosis, a condition where abnormal protein deposits build up in the heart muscle, causing the heart to work less effectively. This particular study focuses on a form of the condition that affects the heart, called variant transthyretin amyloid cardiomyopathy, which has been newly diagnosed in participants. The treatment being studied is Acoramidis, also known by its code name AG10, which is given as a tablet taken by mouth.

The purpose of this study is to evaluate the long-term safety and how well people tolerate acoramidis when taken over an extended period. This is an extension study, which means it continues treatment for people who have already completed an earlier study called ACT-EARLY. Participants who finished that previous study within the past 60 days and who still have the diagnosis can join this extension study to continue receiving the medication.

During the study, participants will take acoramidis tablets regularly, and doctors will monitor them for any side effects or unwanted reactions to the medication. The study will track various health measures including heart function through ultrasound images of the heart, blood tests that measure substances related to heart stress and damage, heart rhythm patterns, and overall health status. Doctors will also watch for any hospitalizations related to heart problems, changes in symptoms, development of heart rhythm disturbances, and other health conditions that can occur with this disease. The study will continue for several years to gather information about the long-term effects of the medication.

]]> Study on Acoramidis for Preventing Transthyretin Amyloidosis in Young People with a Genetic Risk https://clinicaltrials.eu/trial/study-on-acoramidis-for-preventing-transthyretin-amyloidosis-in-young-people-with-a-genetic-risk/ Wed, 29 Apr 2026 15:03:20 +0000 https://clinicaltrials.eu/trial/study-on-acoramidis-for-preventing-transthyretin-amyloidosis-in-young-people-with-a-genetic-risk/ The study focuses on a condition called Transthyretin Amyloidosis, which is a rare disease that can affect the heart and nerves. The trial is investigating a treatment called Acoramidis (AG10), which is taken as a tablet. This treatment is being compared to a placebo to see if it can prevent the disease in people who carry a specific genetic variant but do not yet show symptoms.

The purpose of the study is to determine if Acoramidis can effectively prevent the development of Transthyretin Amyloidosis in individuals who are at risk but currently asymptomatic. Participants will be randomly assigned to receive either the treatment or a placebo. The study will monitor participants over time to see if they develop symptoms of the disease.

The trial is designed to be a long-term study, with participants being followed for several years. The main focus will be on the time it takes for the disease to develop in those taking the treatment compared to those taking the placebo. The study will also look at other health outcomes and any side effects that may occur during the trial period.

]]> Study on the Impact of Dapagliflozin on Quality of Life and Exercise Capacity in Patients with Transthyretin Cardiac Amyloidosis https://clinicaltrials.eu/trial/study-on-the-impact-of-dapagliflozin-on-quality-of-life-and-exercise-capacity-in-patients-with-transthyretin-cardiac-amyloidosis/ Wed, 29 Apr 2026 14:24:05 +0000 https://clinicaltrials.eu/trial/study-on-the-impact-of-dapagliflozin-on-quality-of-life-and-exercise-capacity-in-patients-with-transthyretin-cardiac-amyloidosis/ This clinical trial is focused on studying the effects of a medication called dapagliflozin on patients with a heart condition known as amyloid transthyretin cardiac amyloidosis (ATTR-CA). ATTR-CA is a disease where abnormal protein deposits, called amyloids, build up in the heart, affecting its function. The medication being tested, dapagliflozin, is taken as a film-coated tablet and is commonly used to treat other conditions like diabetes. In this study, researchers aim to understand how dapagliflozin affects the quality of life and exercise capacity of people with ATTR-CA.

The purpose of the study is to determine the impact of dapagliflozin on the ability of patients with ATTR-CA to exercise. Participants in the study will be given either dapagliflozin or a placebo, and their progress will be monitored over a period of time. The study will look at changes in how far patients can walk in six minutes, which is a common way to measure exercise capacity. Additionally, researchers will assess improvements in patients’ overall well-being and any changes in heart-related symptoms.

Throughout the study, the safety of dapagliflozin will be closely monitored by recording any side effects experienced by participants. The study will also evaluate if there are any changes in the use of other heart medications, such as diuretics, which help remove excess fluid from the body. By the end of the study, researchers hope to gather valuable information on how dapagliflozin can benefit patients with ATTR-CA, potentially leading to better treatment options in the future.

]]>